Some recent work using general KO mice and myeloid specific mice for P2X4R, together with a specific antagonist has shown that there is a critical time window, during the acute phase, where P2X4R inhibition is beneficial for the treatment of stroke, whereas a chronic inhibition could lead to an aggravated depressive state due to the lack of secretion of BDNF (Verma et al., 2017; Srivastava et al., 2020). Here, P2RX4 is linked to stroke disorder.